Unfavourable clinicopathologic features and low response rate to systemic adjuvant therapy: results with regard to poor survival in young Chinese breast cancer patients

PURPOSE To evaluate the quality of life (QOL) of breast cancer patients who survived 2 to 5 years following initiation of adjuvant cytotoxic and/or hormonal therapy and to characterize relationships between QOL and patient physical symptoms, sexual function, and preferences regarding adjuvant treatment. PATIENTS AND METHODS Eighty-six patients who had completed systemic adjuvant therapy for early-stage breast cancer between 1988 and 1991 were surveyed by written questionnaire and telephone interview. Sociodemographic information was obtained for each patient, and patients were asked to complete the Functional Living Index-Cancer (FLIC), the Symptom Distress Scale (SDS), the Medical Outcomes Study (MOS) Short Form 36 (SF-36), a series of questions regarding sexual function, and a survey about preferences for adjuvant therapy in relation to possible benefit. RESULTS The mean FLIC score among all patients was 138.3 (+/- 12.2), which suggests a high level of QOL. The reported frequency of moderate to severe symptoms was generally low (ie, < 15%), with fatigue (31.4%), insomnia (23.3%), and local numbness at the site of surgery (22.1%) occurring with greatest frequency. Patients reported a wide range of sexual difficulties. Preference assessment showed that more than 65% of patients were willing to undergo 6 months of chemotherapy for a 5% increase in likelihood of cancer cure. CONCLUSION Self-rated QOL in breast cancer patients 2 to 5 years following adjuvant therapy was generally favorable. Less than one third of patients reported moderate to severe symptoms. Selected aspects of sexual function appeared to be compromised. The majority of patients indicated a willingness to accept 6 months of chemotherapy for small to modest potential benefit.

Download Full-text

Node-negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy

Cancer ◽

10.1002/1097-0142(19900715)66:2<199::aid-cncr2820660202>3.0.co;2-l ◽

1990 ◽

Vol 66 (2) ◽

pp. 199-205 ◽

Cited By ~ 30

Author(s):

Dutzu Rosner ◽

Warren W. Lane

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Cancer Patients ◽

Invasive Breast Cancer ◽

Minimal Invasive ◽

Breast Cancer Patients ◽

Node Negative ◽

Systemic Adjuvant Therapy

Download Full-text

Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy

Acta Oncologica ◽

10.3109/0284186x.2012.713508 ◽

2012 ◽

Vol 52 (1) ◽

pp. 91-101 ◽

Cited By ~ 16

Author(s):

Marit Synnestvedt ◽

Elin Borgen ◽

Hege G. Russnes ◽

Neena T. Kumar ◽

Ellen Schlichting ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Cancer Patients ◽

Early Breast Cancer ◽

Vascular Invasion ◽

Breast Cancer Patients ◽

Ki67 Expression ◽

Combined Analysis ◽

Systemic Adjuvant Therapy

Download Full-text

Lipocalin-1 Expression as a Prognosticator Marker of Survival in Breast Cancer Patients

Breast Care ◽

10.1159/000503168 ◽

2019 ◽

Vol 15 (3) ◽

pp. 272-280 ◽

Cited By ~ 2

Author(s):

Xueyan Zhang ◽

Yingnan Cui ◽

Miao He ◽

Yan Jiao ◽

Zhaoying Yang

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Roc Curve ◽

Cox Regression ◽

The Cancer Genome Atlas ◽

Rank Test ◽

Fisher Exact Test ◽

Clinicopathologic Features ◽

Breast Cancer Patients ◽

Poor Survival

Purpose: LCN1 (lipocalin-1), a gene that encodes tear lipocalin (or von Ebner’s gland protein), is mainly expressed in secretory glands and tissues, such as the lachrymal and lingual gland, and nasal, mammary, and tracheobronchial mucosae. Analysis of the Cancer Genome Atlas (TCGA) Breast Carcinoma (BRCA) level 3 data revealed a relationship between LCN1 expression and survival in breast cancer patients. Methods: The χ2 test and Fisher exact test were applied to analyze the clinical data and RNA sequencing expression data, and the association between LCN1 expression and clinicopathologic features was determined. The receiver-operating characteristic (ROC) curve of LCN1 was drawn to assess its ability as a diagnostic marker, and the optimal cutoff value was obtained from the ROC curve to distinguish groups with high and low LCN1 expression. Cox regression was used to compare both groups, and a log-rank test was applied to calculate p values and compare the Kaplan-Meier curves. Furthermore, GEO datasets were employed for external data validation. Results: Analysis of 1,104 breast cancer patients with a primary tumor revealed that LCN1 was overexpressed in breast cancer. High LCN1 expression was associated with clinicopathologic features and poor survival. Analyzing the area under the ROC curve (AUC) of LCN1, it was found that its diagnostic ability was limited. Multivariate analysis indicated that LCN1 expression is an independent predictor of survival in breast cancer patients. Through validation in GEO datasets, LCN1 expression was higher in tumor than normal tissue of the breast. High LCN1 expression was associated with poor survival in breast cancer patients. Conclusions: High LCN1 expression is an independent prognosticator of a poor prognosis in breast cancer.

Download Full-text

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients

Breast Cancer Research and Treatment ◽

10.1007/s10549-021-06386-2 ◽

2021 ◽

Author(s):

Linda Thorén ◽

Mikael Eriksson ◽

Jonatan D. Lindh ◽

Kamila Czene ◽

Jonas Bergh ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Cancer Patients ◽

Aromatase Inhibitors ◽

Breast Cancer Patients ◽

Cyp2d6 Activity ◽

Systemic Adjuvant Therapy ◽

Treated Breast ◽

Treated Breast Cancer

Abstract Purpose Change in mammographic density has been suggested to be a proxy of tamoxifen response. We investigated the effect of additional adjuvant systemic therapy and CYP2D6 activity on MD change in a cohort of tamoxifen-treated pre- and postmenopausal breast cancer patients. Methods Swedish breast cancer patients (n = 699) operated 2006–2014, genotyped for CYP2D6, having at least three months postoperative tamoxifen treatment, a baseline, and at least one follow-up digital mammogram were included in the study. Other systemic adjuvant treatment included chemotherapy, goserelin, and aromatase inhibitors. Change in MD, dense area, was assessed using the automated STRATUS method. Patients were stratified on baseline characteristics, treatments, and CYP2D6 activity (poor, intermediate, extensive, and ultrarapid). Relative density change was calculated at year 1, 2, and 5 during follow-up in relation to treatments and CYP2D6 activity. Results Mean relative DA decreased under the follow-up period, with a more pronounced MD reduction in premenopausal patients. No significant effect of chemotherapy, aromatase inhibitors, goserelin, or CYP2D6 activity on DA change was found. DA did not revert to baseline levels after tamoxifen discontinuation. Conclusion Our results indicate that other systemic adjuvant therapy does not further reduce MD in tamoxifen-treated breast cancer patients. We could not confirm the previously suggested association between CYP2D6 activity and MD reduction in a clinical setting with multimodality adjuvant treatment. No rebound effect on MD decline after tamoxifen discontinuation was evident.

Download Full-text

Identification of intermediate risk breast cancer patients with1–3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis

The Breast ◽

10.1016/j.breast.2013.07.043 ◽

2013 ◽

Vol 22 (5) ◽

pp. 643-649 ◽

Cited By ~ 3

Author(s):

B.K. Linderholm ◽

S. Linder ◽

L.-G. Arnesson ◽

O. Stål

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Lymph Nodes ◽

Cancer Patients ◽

Intermediate Risk ◽

Breast Cancer Patients ◽

Proliferation And Apoptosis ◽

Systemic Adjuvant Therapy ◽

Risk Breast Cancer ◽

Positive Lymph Nodes

Download Full-text

Lipoplatin Treatment in Lung and Breast Cancer

Chemotherapy Research and Practice ◽

10.1155/2011/125192 ◽

2011 ◽

Vol 2011 ◽

pp. 1-7 ◽

Cited By ~ 6

Author(s):

Manuela Fantini ◽

Lorenzo Gianni ◽

Carlotta Santelmo ◽

Fabrizio Drudi ◽

Cinzia Castellani ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Triple Negative ◽

Response Rate ◽

Toxicity Profile ◽

Phase 2 ◽

Breast Cancer Patients ◽

Phase 3 ◽

Cisplatin Analogues

The introduction of cisplatin in cancer treatment represents an important achievement in the oncologic field. Many types of cancers are now treated with this drug, and in testicular cancer patients major results are reached. Since 1965, other compounds were disovered and among them carboplatin and oxaliplatin are the main Cisplatin analogues showing similar clinical efficacy with a safer toxicity profile. Lipoplatin is a new liposomal cisplatin formulation which seems to have these characteristics. Lipoplatin was shown to be effective in NSCLC both in phase 2 and phase 3 trials, with the same response rate of Cisplatin, a comparable overall survival but less toxicity. A new protocol aiming to elucidate the double capacity of Lipoplatin to act as a chemotherapeutic and angiogenetic agent in triple-negative breast cancer patients is upcoming.

Download Full-text